Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control
Open Access
- 23 June 2017
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 45 (10), 1049-1059
- https://doi.org/10.1124/dmd.116.074567
Abstract
The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency and the Food and Drug Administration have issued guidances for the conduct of drug-drug interaction (DDI) studies. To examine the applicability of these regulatory recommendations specifically for induction, a group of scientists, under the auspices of the Drug Metabolism Leadership Group of the Innovation and Quality (IQ) Consortium, formed the Induction Working Group (WG). A team of 20 scientists, from 16 of the 39 pharmaceutical companies, which are members of the IQ Consortium, and three Contract Research Organizations, reviewed the recommendations, focusing initially on the current EMA guidance. Questions were collated from IQ member companies as to which aspects of the guidance required further evaluation. The EMA was then approached to provide insights into their recommendations on the following points; a) evaluation of down-regulation, b) in vitro assessment of CYP2C induction, c) the recommendation to use CITCO as the positive control for CYP2B6 induction, d) data interpretation (two-fold increase in mRNA as evidence of induction), and e) duration of incubation of hepatocytes with test article. The Induction WG conducted an anonymous survey among IQ member companies to query current practices, specifically focusing on how the aforementioned key points are evaluated. Responses were received from 19 companies. All data/information was blinded prior to being shared with the Induction WG. The results of the survey are presented together with consensus recommendations on down-regulation, CYP2C induction and CYP2B6 positive control. Data interpretation and incubation duration will be reported in subsequent manuscripts.Keywords
This publication has 97 references indexed in Scilit:
- Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and diseaseScientific Reports, 2016
- Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich cultureXenobiotica, 2014
- Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transportersBiochemical Pharmacology, 2012
- Camptothecin Attenuates Cytochrome P450 3A4 Induction by Blocking the Activation of Human Pregnane X ReceptorThe Journal of pharmacology and experimental therapeutics, 2010
- In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America PerspectiveDrug Metabolism and Disposition, 2009
- REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATIONAnnual Review of Pharmacology and Toxicology, 2006
- Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic PathwaysThe Journal of Clinical Pharmacology, 2005
- Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinideEuropean Journal of Clinical Pharmacology, 2004
- The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA PerspectiveThe Journal of Clinical Pharmacology, 2003
- Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19British Journal of Clinical Pharmacology, 1997